Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-049271

Chief Business Development Off sold 6,771 shares at an average $41.30 ($279,648)

  • Chief Business Development Off acquired 6,771 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-09-01 Option exercise +2,604 $6.55 $17,056 2,604 D: show line 1 in the form
BENZENO SHARON Chief Business Development Off 2020-09-01 Option exercise +2,604 $6.55 $17,056 5,208 D: show line 2 in the form
BENZENO SHARON Chief Business Development Off 2020-09-01 Option exercise +1,563 $7.27 $11,363 6,771 D: show line 3 in the form
BENZENO SHARON Chief Business Development Off 2020-09-01 Sale −6,471 $41.28 $267,123 300 D: show line 4 in the form
BENZENO SHARON Chief Business Development Off 2020-09-01 Sale −300 $41.75 $12,525 0 D: show line 5 in the form
Open-market sales · 6,771 sh · avg $41.30 · $279,648

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-09-01 Option exercise · Stock Option (Right to Buy) −2,604 36,459 D: show line 6 in the form
BENZENO SHARON Chief Business Development Off 2020-09-01 Option exercise · Stock Option (Right to Buy) −2,604 65,105 D: show line 7 in the form
BENZENO SHARON Chief Business Development Off 2020-09-01 Option exercise · Common Stock (Right to Buy) −1,563 43,750 D: show line 8 in the form
Loading xslF345X03/doc4.xml…